- INVEGA® For Schizoaffective Disorder
- INVEGA® For Schizophrenia
- Adobe Reader Download
- Prescribing Information
- Important Safety Information
- Legal Notice
- Site Map
- Contact Us
INVEGA® (paliperidone) extended-release tablets are indicated for the treatment of schizophrenia in adults and adolescents (12-17 years of age). The efficacy of INVEGA® in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents (12-17 years of age), as well as one maintenance trial in adults.
INVEGA® (paliperidone) extended-release tablets are indicated for the treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers and/or antidepressant therapy in adults. The efficacy of INVEGA® in schizoaffective disorder was established in two 6-week trials in adults.
Please discuss your symptoms with your healthcare professional. Your healthcare professional will review your symptoms and may consult the established guidelines, which are available in the Diagnostic and Statistical Manual of Mental Disorders, where applicable.